Casey Lafferty, DO
Family Medicine · Philadelphia, PANPI 1578874913
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,685 of the $54,515 with a category attached, or 69.1%. Genentech USA, Inc. accounts for 99.8% of it on its own, with 2 other manufacturers making up the rest. Among family medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $813.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$54K
- Amgen$99
- Merck$13
What the payments were for
- Consulting fees$1,6003%
- Speaking & faculty fees$37,68569%
- Travel & lodging$12,68023%
- Food & beverage$2,5365%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 64 | $54,403 |
| Amgen(2 entities) | 2 | $99 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xofluza$53,895
How this compares
$54,515 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $37,499 |
| JardianceEmpagliflozin | 13 | $13,503 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,152 |
| Duloxetine Hcl | 40 | $791 |
| Atorvastatin Calcium | 41 | $711 |
| Omeprazole | 43 | $688 |
| Cinacalcet Hcl | 12 | $666 |
| Potassium Chloride | 12 | $595 |
| Rosuvastatin Calcium | 46 | $488 |
| Losartan Potassium | 28 | $473 |
| Metformin Hcl ErMetformin Hcl | 37 | $397 |
| Amlodipine Besylate | 51 | $374 |
| Pantoprazole Sodium | 24 | $331 |
| Fluticasone Propionate | 28 | $273 |
| Levothyroxine Sodium | 31 | $226 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Philadelphia
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Glenn RosenPhiladelphia$61K
- Jessica DefflerPhiladelphia$56K
- Margot SavoyPhiladelphia$31K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.